Products & safety
Skin-lightening products: ingredients, jurisdiction and treatment evidence
On this page
Skin-lightening products are marketed to change pigmentation, but ingredient lists and intended treatment claims distinguish different products. FDA warns about mercury and unapproved over-the-counter hydroquinone lighteners. The word brightening alone does not establish an approved medicine, identify an illegal ingredient or demonstrate a health benefit.[1]
Different product properties answer different questions
| Category | What it does or measures | Boundary |
|---|---|---|
| US OTC hydroquinone lightener | An unapproved skin-lightening-drug context | Historical OTC advice does not describe current authorisation[2] |
| Prescription melasma combination | Hydroquinone, tretinoin and fluocinolone | Not maintenance or all pigment conditions[3] |
| UK cosmetic lightener | Cosmetic ingredient restrictions apply | Medicinal indications are a different category[4] |
| Mercury exposure measurement | Measures product or human exposure | Not cosmetic efficacy or every market’s prevalence[6] |
Appearance and availability do not establish contents
FDA says some illegal skin-lightening products may omit mercury or hydroquinone from their labels. It identifies harms including irritation, swelling and ochronosis with hydroquinone reports, and systemic toxicity from mercury. These warnings concern particular substances and illegal products; they do not imply every product labelled brightening contains mercury. A professional-looking package or online listing cannot establish that a product meets the applicable rules. Ingredient uncertainty is a practical reason to avoid assuming that an apparently familiar cosmetic is equivalent to a prescribed treatment.[1]
US over-the-counter advice changed with the legal framework
FDA’s 2022 communication explains that the CARES Act changed the previous pending OTC drug status, effective September 23,2020. OTC skin-lightening drugs now require an approved new-drug application; no OTC hydroquinone lightening product was approved in the described context. The agency’s warning letters addressed companies selling potentially harmful unapproved products. This is a US regulatory distinction, rather than a statement that every prescribed hydroquinone-containing medicine is illegal or that historic advice about 2% OTC products remains current. Regulatory status also does not supply a comparative efficacy estimate.[2]
Cosmetic prohibitions should not be confused with medicines
Southwark’s current UK trading-standards guidance identifies hydroquinone, mercury and potent corticosteroids as prohibited ingredients in cosmetic skin lighteners. It distinguishes legitimate medicinal uses from cosmetic bleaching products. The category matters: a restriction in cosmetics should not be rewritten as a statement that every medicine containing a related ingredient is prohibited. Nor does this local guidance establish every country’s rules. The guide uses the agency’s legal-category explanation, without treating its broader health assertions as independent clinical evidence.[4]
Evidence & uncertainty
An approved prescription combination has a narrower indication than general bleaching. The Tri-Luma label describes short-term treatment of moderate to severe facial melasma with sun avoidance. Its trials and warnings apply to that combination and studied population, not permanent whole-body whitening or every kind of dark mark.[3]
Selected-source overview · Independent review pendingPublished questions
Does old advice about OTC hydroquinone describe current US lightener authorisation?
Selected-source overview · Independent review pending. Read the evidence context.
No. FDA explains the legal change effective September 2020 and the need for approved drug applications. Historical OTC status should not be presented as current approval.[2]
Evidence behind this answer
- FDA protects consumers from potentially harmful OTC skin-lightening products
official guidance · 2022
Selected original guidance or document passages inspected; no independent full-document appraisal · 19 April 2022 communication: CARES Act, effective 23 September 2020 and approved-application requirement
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does the prescription combination establish permanent whole-body whitening?
Selected-source overview · Independent review pending. Read the evidence context.
No. Its label concerns short-term facial melasma treatment, excludes maintenance use and reports bounded eight-week trials. Other sites and pigment conditions are not established by that evidence.[3]
Evidence behind this answer
- Tri-Luma prescribing information
original product label · 2023
Selected original guidance or document passages inspected; no independent full-document appraisal · Selected §§1/5/14: short-term facial melasma, two 8-week trials 641 adults, skin-type limits; listing 24 October 2024, label revisedFebruary 2023
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Can a skin-lightener label omit an illegal ingredient?
Selected-source overview · Independent review pending. Read the evidence context.
Yes. FDA warns that some products may not disclose mercury or hydroquinone. Packaging and a reassuring claim do not independently establish contents or lawful status.[1]
Evidence behind this answer
- Skin Product Safety
official guidance · 2026
Selected original guidance or document passages inspected; no independent full-document appraisal · Selected consumer QAs updated 11 May 2026: mercury/hydroquinone, unapproved OTC products and omitted ingredients
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Do UK cosmetic-lightener ingredient prohibitions ban every medicinal use?
Selected-source overview · Independent review pending. Read the evidence context.
No. The trading-standards explanation distinguishes cosmetics from legitimate medicines. Ingredient, intended use and product category remain important.[4]
Evidence behind this answer
- Illegal skin lighteners
official guidance · 2026
Selected original guidance or document passages inspected; no independent full-document appraisal · Selected cosmetic-prohibition versus medicinal-use category explanation; updated 9 September 2026; broader unsupported medical assertions not adopted
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does the mercury review estimate contamination in every country’s whole market?
Selected-source overview · Independent review pending. Read the evidence context.
No. It summarises selected heterogeneous studies and measurements. Those samples cannot establish universal market prevalence or the contents of every individual product.[6]
Evidence behind this answer
- A Systematic Review of Mercury Exposures from Skin-Lightening Products
original systematic review abstract · 2022
Original published abstract reproduction inspected; original full paper unavailable; no independent full-text appraisal · Published original abstract reproduction inspected:41 papers/22 countries,787 products/1042 biomarkers; full paper and original publisher unavailable
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
Does online sale prove a mercury-containing lightener is authorised?
Selected-source overview · Independent review pending. Read the evidence context.
No. WHO describes continued availability despite national prohibitions. Availability and enforcement are different questions from legal authorisation or health safety.[5]
Evidence behind this answer
- Mercury in skin lightening products
official guidance · 2019
Selected original guidance or document passages inspected; no independent full-document appraisal · Official information-note overview inspected: health hazard and availability despite bans; six-page note itself not inspected
This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.
A facial-melasma label has bounded efficacy data
The prescription label reports two eight-week controlled trials involving 641 adults aged 21–75 with skin types I–IV. The triple combination was compared with three dual combinations, and complete clearing varied between trials. Against hydroquinone plus tretinoin, clearing was 38% versus 15% in one trial and 13% versus 4% in the other. These are study-specific appearance outcomes, not a guarantee of permanent clearing. Skin types V–VI were not studied. The indication excludes maintenance treatment and does not establish benefit for all hyperpigmentation conditions.[3]
Mercury measurements show heterogeneous exposure
The 2022 systematic-review abstract describes 41 papers from 22 countries, with 787 products and 1,042 biomarker measurements among 863 people. Mercury exposures varied widely, and some harms were self-reported. These selected studies do not estimate the prevalence of mercury in every national market or prove that a specific pictured product contains it. Their focus is exposure and potential harm, not comparative lightening efficacy. The inspected published abstract supports these broad findings; limited access prevents a full appraisal of sampling methods, analytical quality and all individual study interpretations.[6]
National bans and actual availability can diverge
WHO’s information-note overview describes the health hazard of mercury-containing lighteners and continued availability, including online, despite prohibitions in many countries. Availability is therefore a poor substitute for checking authorisation and contents. Enforcement and market coverage vary, so one country’s restriction cannot establish the status of every imported product. The inspected overview does not provide a complete legal survey or justify a precise treaty threshold. Clinical treatment of a pigment condition is a different decision from choosing a product marketed for general skin bleaching.[5]
References
- Skin Product Safety
Official guidance
FDA · Content/publication date: 2026
Accessed: 2026-10-14 UTC · Selected original guidance or document passages inspected; no independent full-document appraisal
Cited sections: Selected consumer QAs updated 11 May 2026: mercury/hydroquinone, unapproved OTC products and omitted ingredients - FDA protects consumers from potentially harmful OTC skin-lightening products
Official guidance
FDA · Content/publication date: 2022
Accessed: 2026-10-14 UTC · Selected original guidance or document passages inspected; no independent full-document appraisal
Cited sections: 19 April 2022 communication: CARES Act, effective 23 September 2020 and approved-application requirement - Tri-Luma prescribing information
Original product label
DailyMed / Galderma · Content/publication date: 2023
Accessed: 2026-10-14 UTC · Selected original guidance or document passages inspected; no independent full-document appraisal
Cited sections: Selected §§1/5/14: short-term facial melasma, two 8-week trials 641 adults, skin-type limits; listing 24 October 2024, label revisedFebruary 2023 - Illegal skin lighteners
Official guidance
Southwark Council Trading Standards · Content/publication date: 2026
Accessed: 2026-10-14 UTC · Selected original guidance or document passages inspected; no independent full-document appraisal
Cited sections: Selected cosmetic-prohibition versus medicinal-use category explanation; updated 9 September 2026; broader unsupported medical assertions not adopted - Mercury in skin lightening products
Official guidance
World Health Organization · Content/publication date: 2019
Accessed: 2026-10-14 UTC · Selected original guidance or document passages inspected; no independent full-document appraisal
Cited sections: Official information-note overview inspected: health hazard and availability despite bans; six-page note itself not inspected - A Systematic Review of Mercury Exposures from Skin-Lightening Products
Original systematic review abstract
Bastiansz et al. · Content/publication date: 2022
Accessed: 2026-10-14 UTC · Original published abstract reproduction inspected; original full paper unavailable; no independent full-text appraisal
Cited sections: Published original abstract reproduction inspected:41 papers/22 countries,787 products/1042 biomarkers; full paper and original publisher unavailableDOI 10.1289/EHP 10808; published abstract, not the different preprint search period.
Scope & review
- Population
- General consumers; children, clinical patients and occupational exposure are identified separately
- Exposure or intervention
- Product functions, ingredient-specific claims and practical personal-care boundaries
- Comparison
- Regulatory category versus availability; prescribed facial-melasma treatment versus general bleaching; exposure biomarkers versus cosmetic efficacy
- Outcomes
- Appearance, handling, source-specific clinical outcomes, irritation and other identified harms
- Timeframe
- Current guidance checked 14 October 2026 UTC; original study populations and timeframes are stated separately
- Jurisdiction
- US FDA drug/cosmetic context, selected current UK trading-standards explanation and WHO global overview; not a comprehensive international legal survey
Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.
Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.
Revision history
- 2026-10-14 UTC: Added a sourced explanation in a bounded ten-article batch; qualified review remains pending.
What this article still leaves open
- Which contents and authorisation can be established for a specific imported product?
- How do treatment responses and harms vary in under-studied skin types and with sustained use?
Suggest a correction
Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.
Your submitted corrections for this article
Explore the topic map
Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.